Navigation Links
Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
Date:3/3/2009

SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) (http://www.BMSN.us), an emerging research and development biotechnology company focused on the full spectrum of adult stem cells at its commercial cryogenic stem cell bank and processing facility located here, is highlighted in a News/Special Report about trends in adult stem cells published this week as an exclusive to online LifeSciencesWorld (http://www.LifeSciencesWorld.com) that projects the overall market to exceed $8 billion worldwide by 2016 and the umbilical cord blood market estimated to reach approximately $1 billion by 2010.

The Special Report, "Discoveries of Stem Cell Derived from Menstrual Blood Significant Step Forward to Transplantation as Industry Focuses on Other Principle Sources in Therapeutics" by New York City-based author and writer Sally Robbins, provides an overview of the sector, including how a new type of stem cell derived from menstrual blood and other discoveries are providing significant steps forward in providing an ethical, easily accessible, and potentially highly useful adult stem cell for treatment of numerous degenerative conditions.

David Koos, Chairman and CEO of BMSN, is quoted in the report stating: "The recent discovery of the novel stem cell population in menstrual blood and related findings are scientific breakthroughs that are opening the doors to a new dimension in private stem cell/family banking, which has been primarily focused on umbilical cord blood." The report also reviews how BMSN is poised for growth by focusing on the full scope of adult stem cells: cord blood, peripheral blood, bone marrow, menstrual blood and adipose (fat) tissue by forging strategic partnerships in bringing together the necessary resources to offer key technologies in stem cell cryogenics, therapies and bio-medical devices for improving the quality of life.

The article also chronicles in-depth the new developments in umbilical cord blood technologies and the ways in which private stem cell banks in the industry are consolidating.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company that commercializes medical devices and monitoring systems for the growing worldwide stem cell research market. Its new facility houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
2. Bio-Matrix Scientific Group Announces New Hires to Management Team
3. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
4. Edmond Scientific Company Spotlight on the Executive:
5. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
6. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
7. Weed Science Society of America Announces Winners in Annual Scientific Awards Program
8. Arts Way Manufacturing Announces Launch of New Web Site For Arts Way Scientific - Buildings For Science
9. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
10. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
11. BioSpace Partners with Journal of Visualized Experiments (JoVE) to Offer Peer-Reviewed Scientific Video Content on BioSpace.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):